A 62-year-old with nonsevere CDI asks about bezlotoxumab. Which statement aligns with guidance?...

Question

A 62-year-old with nonsevere CDI asks about bezlotoxumab. Which statement aligns with guidance?

Accepted Answer

May be considered to reduce recurrence risk in high-risk patients

Answer

Not indicated for initial CDI

Answer

Replaces antibiotics

Answer

For fulminant CDI only

Answer

Contraindicated in heart failure

"us-abim MCQ (SBA): CDI Recurrence Prevention